Tsai Chin-Han, Liao Ko-Hsun, Shih Chuan-Chi, Chan Chia-Hao, Hsieh Jui-Yu, Tsai Cheng-Fong, Wang Hsei-Wei, Chang Shing-Jyh
1 Department of Obstetrics and Gynecology, Hsinchu Mackay Memorial Hospital , Hsinchu, Taiwan .
2 Institute of Microbiology and Immunology.
OMICS. 2016 Mar;20(3):191-8. doi: 10.1089/omi.2015.0136. Epub 2016 Feb 24.
Organ regeneration therapies using multipotent mesenchymal stem cells (MSCs) are currently being investigated for a variety of common complex diseases. Understanding the molecular regulation of MSC biology will benefit regenerative medicine. MicroRNAs (miRNAs) act as regulators in MSC stemness. There are approximately 2500 currently known human miRNAs that have been recorded in the miRBase v21 database. In the present study, we identified novel microRNAs involved in MSC stemness and differentiation by obtaining the global microRNA expression profiles (miRNomes) of MSCs from two anatomical locations bone marrow (BM-MSCs) and umbilical cord Wharton's jelly (WJ-MSCs) and from osteogenically and adipogenically differentiated progenies of BM-MSCs. Small RNA sequencing (smRNA-seq) and bioinformatics analyses predicted that 49 uncharacterized miRNA candidates had high cellular expression values in MSCs. Another independent batch of Ago1/2-based RNA immunoprecipitation (RNA-IP) sequencing datasets validated the existence of 40 unreported miRNAs in cells and their associations with the RNA-induced silencing complex (RISC). Nine of these 40 new miRNAs were universally overexpressed in both MSC types; nine others were overexpressed in differentiated cells. A novel miRNA (UNI-118-3p) was specifically expressed in BM-MSCs, as verified using RT-qPCR. Taken together, this report offers comprehensive miRNome profiles for two MSC types, as well as cells differentiated from BM-MSCs. MSC transplantation has the potential to ameliorate degenerative disorders and repair damaged tissues. Interventions involving the above 40 new microRNA members in transplanted MSCs may potentially guide future clinical applications.
目前正在研究使用多能间充质干细胞(MSC)进行器官再生治疗,以治疗多种常见的复杂疾病。了解MSC生物学的分子调控将有助于再生医学。微小RNA(miRNA)在MSC干性中起调节作用。miRBase v21数据库中目前已记录了约2500种已知的人类miRNA。在本研究中,我们通过获取来自两个解剖位置的MSC的全局微小RNA表达谱(miRNome),即骨髓(BM-MSC)和脐带华通氏胶(WJ-MSC),以及来自BM-MSC的成骨和成脂分化后代,鉴定了参与MSC干性和分化的新型微小RNA。小RNA测序(smRNA-seq)和生物信息学分析预测,49个未表征的miRNA候选物在MSC中具有高细胞表达值。另一批基于Ago1/2的RNA免疫沉淀(RNA-IP)测序数据集独立验证了细胞中40种未报道的miRNA的存在及其与RNA诱导沉默复合体(RISC)的关联。这40种新miRNA中有9种在两种MSC类型中均普遍过表达;另外9种在分化细胞中过表达。使用RT-qPCR验证,一种新型miRNA(UNI-118-3p)在BM-MSC中特异性表达。综上所述,本报告提供了两种MSC类型以及从BM-MSC分化而来的细胞的全面miRNome图谱。MSC移植有可能改善退行性疾病并修复受损组织。涉及移植的MSC中上述40个新的微小RNA成员的干预措施可能会指导未来的临床应用。